NOVO-B - Novo Nordisk A/S - Stock Price & Dividends

Novo Nordisk A/S is a leading global healthcare company that focuses on developing innovative solutions to improve the lives of people with diabetes and other serious diseases. Through its subsidiaries, the company engages in the research, development, manufacturing, and distribution of pharmaceutical products across various regions, including Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and other international markets.

Novo Nordisk A/S operates through two main segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment provides a range of products that address diabetes, obesity, cardiovascular health, and emerging therapy areas. This segment is committed to helping people manage their diabetes and obesity through innovative treatments and solutions.

The Rare Disease segment offers products that cater to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. This segment aims to improve the lives of people affected by rare diseases through its specialized products and services.

In addition to its pharmaceutical products, Novo Nordisk A/S also provides various accessories and tools, such as insulin pens, growth hormone pens, and injection needles, to make it easier for people to manage their conditions. The company also offers smart solutions, including smart insulin pens and the Dose Check application, which helps people with diabetes track their insulin doses and make informed decisions about their treatment.

Novo Nordisk A/S has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products, further expanding its reach and capabilities. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Its commitment to innovation, quality, and customer satisfaction has made it a leader in the global healthcare industry. You can learn more about the company and its activities on its website: https://www.novonordisk.com